14-day Premium Trial Subscription Sign Up For FreeGet Free

Axsome Therapeutics Stock Forecast NASDAQ:AXSM

Price Target and Analyst Ratings

Most Recent Rating

On September 15, 2021 "HC Wainwright" gave "$180.00" rating for AXSM. The price target was set to $28.38+8.4%.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-09-15 $180.00 Reiterated by HC Wainwright $27.72 $28.38+8.4%
2021-08-30 $225.00 - $180.00 Reiterated by HC Wainwright $24.38 $24.00+3.2%
2021-08-30 $225.00 - $180.00 Target Lowered by HC Wainwright $24.38 $24.25+1.0%
2021-08-27 Reiterated by William Blair $24.00 $24.02+3.3%
2021-08-23 $55.00 Reiterated by Mizuho $24.79 $22.89+6.2%
2021-08-10 $200.00 - $160.00 Target Lowered by Truist Securities $23.78 $24.04→12.2%
2021-08-10 $118.00 - $55.00 Target Lowered by Mizuho $23.78 $27.37→46.5%
2021-08-10 $105.00 - $34.00 Downgraded by Morgan Stanley $23.78 $27.37→46.5%
2021-08-10 $200.00 - $160.00 Target Lowered by Truist $23.78 $23.70→13.4%
2021-08-10 $115.00 - $75.00 Target Lowered by SVB Leerink $23.78 $23.70→13.4%
2021-08-10 $123.00 - $55.00 Target Lowered by BTIG Research $23.78 $23.42→14.4%
2021-07-16 $56.77 Target Set by William Blair $54.22 $55.02→3.1%
2021-07-16 Reiterated by William Blair $54.22 $56.77→0.1%
2021-06-10 Buy Initiated by Berenberg Bank $67.57 $112.00
2021-05-26 Overweight Target Raised by Morgan Stanley $56.23 $104.00 → $105.00
2021-05-12 Buy Reiterated by BTIG Research $57.01
2021-05-03 Buy Target Raised by HC Wainwright $61.55 $210.00 → $225.00
2021-04-27 Buy Target Raised by HC Wainwright $60.39 $210.00 → $225.00
2021-04-27 Buy Reiterated by HC Wainwright $60.39 $210.00 → $225.00
2021-03-08 Overweight Target Raised by Morgan Stanley $62.82 $101.00 → $104.00
2021-03-02 Overweight Target Raised by Morgan Stanley $69.76 $101.00 → $104.00
2021-03-02 Buy Target Lowered by Mizuho $69.76 $120.00 → $118.00
2021-01-08 Buy Initiated by Jefferies Financial Group $77.71 $129.00
2020-12-31 Positive Reiterated by UBS Group $81.47
2020-12-15 Buy Initiated by Mizuho $80.05 $120.00
2020-12-15 Buy Initiated by Mizuho $80.05
2020-12-03 Positive - Overweight Target Raised by Cantor Fitzgerald $77.15 $131.00 → $161.00
2020-11-09 Overweight Target Lowered by Morgan Stanley $68.82 $102.00 → $101.00
2020-10-01 Buy Reiterated by William Blair $72.21
2020-09-29 Underperform Initiated by BofA Securities $72.28 $66.00
2020-09-29 Underperform Initiated by Bank of America $72.28 $66.00
2020-09-10 Overweight Initiated by Morgan Stanley $73.03 $102.00
2020-08-21 Buy Reiterated by William Blair $77.57
2020-08-10 Buy Reiterated by William Blair $81.79
2020-08-06 Buy Reiterated by HC Wainwright $78.04 $210.00
2020-07-14 Buy Reiterated by HC Wainwright $79.42 $210.00
2020-06-30 Buy Reiterated by HC Wainwright $82.28 $210.00
2020-04-28 Buy Target Raised by HC Wainwright $96.35 $200.00 → $210.00
2020-04-28 In-Line - Buy Target Raised by Guggenheim $96.35 $158.00 → $200.00
2020-04-27 Positive - Buy Target Raised by SunTrust Banks $95.00 $145.00 → $200.00
2020-04-27 Overweight Target Raised by Cantor Fitzgerald $95.00 $125.00 → $131.00
2020-04-27 Positive - Buy Target Raised by LADENBURG THALM/SH SH $95.00 $165.00 → $186.00
2020-04-14 Outperform Initiated by Cowen $65.91 $95.00

AXSM Stock Trend

Given the current short-term trend, the stock is expected to fall -67.30% during the next 3 months and, with a 90% probability hold a price between $0.72 and $9.33 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Data

Date Bottom Mid Top
2021-09-20 $1.27 $14.43 $27.60
2021-09-21 $0.34 $13.50 $26.67
2021-09-22 $-0.60 $12.57 $25.73
2021-09-23 $-1.53 $11.64 $24.80
2021-09-24 $-2.46 $10.70 $23.87
2021-09-27 $-3.39 $9.77 $22.94
2021-09-28 $-4.32 $8.84 $22.01
2021-09-29 $-5.26 $7.91 $21.07
2021-09-30 $-6.19 $6.98 $20.14
2021-10-01 $-7.12 $6.04 $19.21
2021-10-04 $-8.05 $5.11 $18.28
2021-10-05 $-8.99 $4.18 $17.34
2021-10-06 $-9.92 $3.25 $16.41
2021-10-07 $-10.85 $2.32 $15.48
2021-10-08 $-11.78 $1.38 $14.55
2021-10-11 $-12.71 $0.45 $13.62
2021-10-12 $-13.65 $-0.48 $12.68
2021-10-13 $-14.58 $-1.41 $11.75
2021-10-14 $-15.51 $-2.35 $10.82
2021-10-15 $-16.44 $-3.28 $9.89
2021-10-18 $-17.37 $-4.21 $8.96
2021-10-19 $-18.31 $-5.14 $8.02
2021-10-20 $-19.24 $-6.07 $7.09
2021-10-21 $-20.17 $-7.01 $6.16
2021-10-22 $-21.10 $-7.94 $5.23
2021-10-25 $-22.03 $-8.87 $4.30
2021-10-26 $-22.97 $-9.80 $3.36
2021-10-27 $-23.90 $-10.73 $2.43
2021-10-28 $-24.83 $-11.67 $1.50
2021-10-29 $-25.76 $-12.60 $0.57

About Axsome Therapeutics

Axsome Therapeutics Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, develops therapies for the management and treatment of central nervous system disorders. Its product candidates include AXS-02, which is in Phase III trial for the treatment of complex regional pain syndrome, knee osteoarthritis, and chronic low back pain; and AXS-05 that is in Phase III trial for the treatment of resistant depression and agitation in patients with Alzheimer's... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT